JP2011521927A - ブリバラセタムを含む医薬組成物 - Google Patents
ブリバラセタムを含む医薬組成物 Download PDFInfo
- Publication number
- JP2011521927A JP2011521927A JP2011511013A JP2011511013A JP2011521927A JP 2011521927 A JP2011521927 A JP 2011521927A JP 2011511013 A JP2011511013 A JP 2011511013A JP 2011511013 A JP2011511013 A JP 2011511013A JP 2011521927 A JP2011521927 A JP 2011521927A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- brivaracetam
- tablet core
- total weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 65
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 title claims abstract description 52
- 229960002161 brivaracetam Drugs 0.000 title claims abstract description 51
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 36
- 239000000314 lubricant Substances 0.000 claims description 36
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 32
- 239000011159 matrix material Substances 0.000 claims description 30
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 25
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 25
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 24
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 24
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 24
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 24
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 23
- 239000011230 binding agent Substances 0.000 claims description 23
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 19
- 239000008119 colloidal silica Substances 0.000 claims description 19
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 19
- 239000008101 lactose Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 19
- 239000008187 granular material Substances 0.000 claims description 17
- 239000003085 diluting agent Substances 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 16
- 229920000642 polymer Polymers 0.000 claims description 15
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 13
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 12
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 12
- 238000005550 wet granulation Methods 0.000 claims description 12
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 238000007907 direct compression Methods 0.000 claims description 10
- 229920000609 methyl cellulose Polymers 0.000 claims description 7
- 235000010981 methylcellulose Nutrition 0.000 claims description 7
- 239000001923 methylcellulose Substances 0.000 claims description 7
- 229920002261 Corn starch Polymers 0.000 claims description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 5
- 239000008120 corn starch Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 31
- 150000001875 compounds Chemical class 0.000 description 22
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 19
- 229920003091 Methocel™ Polymers 0.000 description 19
- 229960001375 lactose Drugs 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 14
- 239000000843 powder Substances 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 239000012071 phase Substances 0.000 description 8
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 7
- 239000012736 aqueous medium Substances 0.000 description 7
- 239000004067 bulking agent Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 229920001477 hydrophilic polymer Polymers 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 6
- -1 hydroxypropyl Chemical group 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000008385 outer phase Substances 0.000 description 6
- 239000008363 phosphate buffer Substances 0.000 description 6
- 238000013268 sustained release Methods 0.000 description 6
- 239000012730 sustained-release form Substances 0.000 description 6
- 229920003084 Avicel® PH-102 Polymers 0.000 description 5
- 206010015037 epilepsy Diseases 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 229960003943 hypromellose Drugs 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 4
- 208000016285 Movement disease Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- 239000006057 Non-nutritive feed additive Substances 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 201000006517 essential tremor Diseases 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000008384 inner phase Substances 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229960003511 macrogol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000021722 neuropathic pain Diseases 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 229960004274 stearic acid Drugs 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000001319 vasomotor rhinitis Diseases 0.000 description 1
- 239000003232 water-soluble binding agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
5.0から80.0%の親水性マトリックス剤、
0.0から75%の希釈剤、
0.0から80%の結合剤、
0.0から3.0%の滑沢剤、及び
0.0から5.50%の潤滑剤
を含む。
10.0から75.0%の親水性マトリックス剤、
0.0から60%の希釈剤、
1.0から70%の結合剤、
0.0から2.5%の滑沢剤、及び
0.0から3.5%の潤滑剤
を含む医薬組成物に関する。
15.0から70%の親水性マトリックス剤、
0.0から40%の希釈剤、
2.0から60%の結合剤、
0.0から2.0%の滑沢剤、及び
0.4から1.3%の潤滑剤
を含む医薬組成物に関する。
5.0から80%のヒドロキシプロピルメチルセルロース、
0.0から75%のラクトース、
0.0から80%の微結晶性セルロース、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含む医薬組成物に関する。
10から75%のヒドロキシプロピルメチルセルロース、
0.0から60%のラクトース、
1.0から70%の微結晶性セルロース、
0.0から2.5%の無水コロイダルシリカ、及び
0.0から3.5%のステアリン酸マグネシウム
を含む医薬組成物に関する。
25から60%のヒドロキシプロピルメチルセルロース、
0.0から40%のラクトース、
2.0から60%の微結晶性セルロース、
0.0から2.0%の無水コロイダルシリカ、及び
0.4から1.3%のステアリン酸マグネシウム
を含む医薬組成物に関する。
5.0から80%のヒドロキシプロピルメチルセルロース、
0から5%のポリビニルピロリドン、
0.0から80%の微結晶性セルロース、
0.0から40%のラクトース、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含む医薬組成物に関する。
10から75%のヒドロキシプロピルメチルセルロース、
0から3%のポリビニルピロリドン、
0.0から30%のラクトース、
1.0から70%の微結晶性セルロース、
0.0から2.5%の無水コロイダルシリカ、及び
0.0から3.5%のステアリン酸マグネシウム
を含む医薬組成物に関する。
25から60%のヒドロキシプロピルメチルセルロース、
0から2%のポリビニルピロリドン、
0.0から20%のラクトース、
2.0から60%の微結晶性セルロース、
0.0から2.0%の無水コロイダルシリカ、及び
0.4から1.3%のステアリン酸マグネシウム
を含む医薬組成物に関する。
5.0から80%のヒドロキシプロピルメチルセルロース、
0.0から80%の微結晶性セルロース、
0.0から75%のラクトース、
0.0から40%のアルファ化されたトウモロコシデンプン、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含む医薬組成物に関する。
10から75%のヒドロキシプロピルメチルセルロース、
1.0から70%の微結晶性セルロース、
0.0から60%のラクトース、
0.0から30%のアルファ化されたトウモロコシデンプン、
0.0から2.5重量%の無水コロイダルシリカ、及び
0.0から3.5重量%のステアリン酸マグネシウム
を含む医薬組成物に関する。
25から60%のヒドロキシプロピルメチルセルロース、
2.0から60%の微結晶性セルロース、
0.0から40%のラクトース、
0.0から20%のアルファ化されたトウモロコシデンプン、
0.0から2.0%の無水コロイダルシリカ、及び
0.4から1.3%のステアリン酸マグネシウム
を含む医薬組成物に関する。
1.ブリバラセタムを純水中に溶解して、適当な用量まで粉末床上に噴霧する。
2.続いて、得られた顆粒を乾燥し、粉砕して外相と混合する。
3.顆粒を圧縮し錠剤にする。
1.ブリバラセタムを純水中に溶解して、適当な用量まで粉末床上に噴霧する。
2.続いて、得られた顆粒を乾燥し、粉砕して外相と混合する。
3.顆粒を圧縮し錠剤にする。
1.ブリバラセタムを純水中に溶解して、適当な用量まで粉末床上に噴霧する。
2.続いて、得られた顆粒を乾燥し、粉砕して外相と混合する。
3.顆粒を圧縮し錠剤にする。
1.ブリバラセタムを純水中に溶解して、適当な用量まで粉末床上に噴霧する。
2.続いて、得られた顆粒を乾燥し、粉砕して外相と混合する。
3.顆粒を圧縮し錠剤にする。
Claims (16)
- 有効成分としてブリバラセタム及び、錠剤コア内の賦形剤として、錠剤のコアの合計重量に対して5%から80重量%の少なくとも1種の親水性マトリックス剤を含む錠剤の形態である医薬組成物であって、親水性マトリックス剤は2パーセント水溶液(20℃)中で100mPa・sを超える粘度を有するポリマーである上記医薬組成物。
- ブリバラセタムを含有する顆粒及び少なくとも1種の親水性マトリックス剤を含有する外相を含む、請求項1に記載の医薬組成物。
- ブリバラセタムと親水性マトリックス剤としての水分散性の速度制御ポリマーとを含む、請求項1に記載の医薬組成物。
- 20から60重量%の親水性マトリックス剤を含む、請求項1に記載の医薬組成物。
- 親水性マトリックス剤が、ヒドロキシプロピルメチルセルロース、ヒドロキシプロピルセルロース、メチルセルロース、ナトリウムカルボキシメチルセルロース、ヒドロキシエチルセルロース、及びポリエチレンオキシドである、請求項1から4までのいずれか一項に記載の医薬組成物。
- 親水性マトリックス剤が親水性ゲル形成ポリマーである、請求項1から5までのいずれか一項に記載の医薬組成物。
- 親水性マトリックス剤が、非セルロース多糖、ポリビニルピロリドン、ポリ酢酸ビニル、アクリル酸ポリマー、又は前記物質の2つ以上の混合物である、請求項1から6までのいずれか一項に記載の医薬組成物。
- 錠剤のコアの比表面積が2mm−1と0.3mm−1との間に含まれる、請求項1から7までのいずれか一項に記載の医薬組成物。
- 錠剤のコアの合計重量に対して0.0から1.5重量%の滑沢剤を含む、請求項1に記載の医薬組成物。
- 錠剤のコアの合計重量に対して0.5から2.0重量%の潤滑剤を含む、請求項1に記載の医薬組成物。
- 錠剤のコアの合計重量に対して1から70重量%の結合剤を含む、請求項1に記載の医薬組成物。
- 結合剤として、2パーセント水溶液中で500mPa・s未満の粘度を有する水溶性ポリマーを含む、請求項11に記載の医薬組成物。
- 有効成分としてブリバラセタム、及び錠剤のコアの合計重量に対して、
5.0から80.0%の親水性マトリックス剤、
0.0から75%の希釈剤、
0.0から80%の結合剤、
0.0から3.0%の滑沢剤、及び
0.0から5.5%の潤滑剤
を含む、請求項1に記載の医薬組成物。 - 有効成分としてブリバラセタム、及び錠剤のコアの合計重量に対して、
5.0から80%のヒドロキシプロピルメチルセルロース、
0.0から75%のラクトース、
0.0から80%の微結晶性セルロース、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含み、
直接圧縮により調製される、請求項1に記載の医薬組成物。 - 有効成分としてブリバラセタム、及び錠剤のコアの合計重量に対して、
5.0から80%のヒドロキシプロピルメチルセルロース、
0.0から80%の微結晶性セルロース、
0.0から40%のラクトース、
0.0から5%のポリビニルピロリドン、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含み、
湿式造粒により調製される、請求項1に記載の医薬組成物。 - 有効成分としてブリバラセタム、及び錠剤のコアの合計重量に対して、
5.0から80%のヒドロキシプロピルメチルセルロース、
0.0から80%の微結晶性セルロース、
0.0から75%のラクトース、
0.0から40%のアルファ化されたトウモロコシデンプン、
0.0から3.0%の無水コロイダルシリカ、及び
0.0から5.5%のステアリン酸マグネシウム
を含み、
湿式造粒により調製される、請求項1に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08009919 | 2008-05-30 | ||
EP08009919.5 | 2008-05-30 | ||
PCT/EP2009/056570 WO2009144286A1 (en) | 2008-05-30 | 2009-05-28 | Pharmaceutical compositions comprising brivaracetam |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011521927A true JP2011521927A (ja) | 2011-07-28 |
JP5553452B2 JP5553452B2 (ja) | 2014-07-16 |
Family
ID=39714168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011511013A Active JP5553452B2 (ja) | 2008-05-30 | 2009-05-28 | ブリバラセタムを含む医薬組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US8435564B2 (ja) |
EP (1) | EP2285357B8 (ja) |
JP (1) | JP5553452B2 (ja) |
CN (1) | CN102046153B (ja) |
BR (1) | BRPI0912161A2 (ja) |
CA (1) | CA2722093C (ja) |
DK (1) | DK2285357T3 (ja) |
ES (1) | ES2465478T3 (ja) |
HK (1) | HK1153141A1 (ja) |
PL (1) | PL2285357T3 (ja) |
WO (1) | WO2009144286A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013537238A (ja) * | 2010-09-21 | 2013-09-30 | インテクリン・セラピユーテイクス・インコーポレイテツド | 抗糖尿病固体医薬組成物 |
JP2020532533A (ja) * | 2017-08-31 | 2020-11-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | 医薬剤形 |
JP2022542533A (ja) * | 2020-07-09 | 2022-10-05 | 上海博志研新薬物技術有限公司 | ブリバラセタム医薬組成物、その製造方法及び応用 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2563339A1 (en) * | 2010-04-29 | 2013-03-06 | Lupin Limited | Controlled release pharmaceutical compositions of brivaracetam |
US10973783B2 (en) | 2015-12-30 | 2021-04-13 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
AU2018280866A1 (en) * | 2017-06-09 | 2019-12-12 | Zoetis Broomhill Ip Limited | Intramammary veterinary composition |
CN109833300A (zh) * | 2017-11-28 | 2019-06-04 | 浙江京新药业股份有限公司 | 一种抗癫痫药物口服组合物及其制备方法 |
CN110638743B (zh) * | 2019-10-25 | 2023-03-28 | 乐普制药科技有限公司 | 一种含布立西坦的组合物 |
CN111407738A (zh) * | 2020-04-03 | 2020-07-14 | 江苏艾立康药业股份有限公司 | 一种布立西坦控释制剂及其制备方法 |
WO2022193723A1 (zh) * | 2021-03-17 | 2022-09-22 | 长沙晶易医药科技有限公司 | 一种组合物及其制备方法和用途 |
CN115192572B (zh) * | 2021-04-08 | 2023-09-19 | 成都同道慧宜生物医药科技有限公司 | 布立西坦药剂、其制备方法和应用 |
CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
CN118450889A (zh) * | 2021-12-27 | 2024-08-06 | 广东东阳光药业股份有限公司 | 布立西坦片剂及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080029A1 (en) * | 2005-01-27 | 2006-08-03 | Alembic Limited | Extended release formulation of levetiracetam |
WO2006090275A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Limited | Treatment of incontinence |
JP2006335771A (ja) * | 2006-09-22 | 2006-12-14 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
WO2007058593A1 (en) * | 2005-11-18 | 2007-05-24 | Astrazeneca Ab | Quetiapine in a controlled release formulation |
WO2007062228A1 (en) * | 2005-11-28 | 2007-05-31 | Orexigen Therapeutics, Inc. | Sustained-release formulation of zonisamide |
WO2007081341A1 (en) * | 2006-01-11 | 2007-07-19 | Teva Phamaceutical Industries Ltd. | Controlled release formulation of divalproic acid and its derivatives |
WO2008046052A1 (en) * | 2006-10-12 | 2008-04-17 | Abbott Laboratories | Pharmaceutical formulations |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
EP1769092A4 (en) | 2004-06-29 | 2008-08-06 | Europ Nickel Plc | IMPROVED LIXIVIATION OF BASE METALS |
KR101280096B1 (ko) | 2005-06-29 | 2013-06-28 | 컴퓨메딕스 리미티드 | 전도성 브리지를 포함하는 센서 어셈블리 |
US8338621B2 (en) * | 2005-12-21 | 2012-12-25 | Ucb S.A. | Process for the preparation of 2-oxo-1-pyrrolidine derivatives |
EP2041084B1 (en) * | 2006-06-08 | 2013-11-06 | UCB Pharma, S.A. | Co-crystals of pyrrolidinones |
-
2009
- 2009-05-28 WO PCT/EP2009/056570 patent/WO2009144286A1/en active Application Filing
- 2009-05-28 EP EP09753941.5A patent/EP2285357B8/en not_active Revoked
- 2009-05-28 JP JP2011511013A patent/JP5553452B2/ja active Active
- 2009-05-28 US US12/993,704 patent/US8435564B2/en active Active
- 2009-05-28 ES ES09753941.5T patent/ES2465478T3/es active Active
- 2009-05-28 BR BRPI0912161A patent/BRPI0912161A2/pt not_active IP Right Cessation
- 2009-05-28 CA CA2722093A patent/CA2722093C/en active Active
- 2009-05-28 DK DK09753941.5T patent/DK2285357T3/da active
- 2009-05-28 PL PL09753941T patent/PL2285357T3/pl unknown
- 2009-05-28 CN CN200980120221.XA patent/CN102046153B/zh active Active
-
2011
- 2011-07-14 HK HK11107321.2A patent/HK1153141A1/xx unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080029A1 (en) * | 2005-01-27 | 2006-08-03 | Alembic Limited | Extended release formulation of levetiracetam |
WO2006090275A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Limited | Treatment of incontinence |
WO2007058593A1 (en) * | 2005-11-18 | 2007-05-24 | Astrazeneca Ab | Quetiapine in a controlled release formulation |
WO2007062228A1 (en) * | 2005-11-28 | 2007-05-31 | Orexigen Therapeutics, Inc. | Sustained-release formulation of zonisamide |
WO2007081341A1 (en) * | 2006-01-11 | 2007-07-19 | Teva Phamaceutical Industries Ltd. | Controlled release formulation of divalproic acid and its derivatives |
JP2006335771A (ja) * | 2006-09-22 | 2006-12-14 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
WO2008046052A1 (en) * | 2006-10-12 | 2008-04-17 | Abbott Laboratories | Pharmaceutical formulations |
Non-Patent Citations (3)
Title |
---|
JPN5011001443; VON ROSENSTIEL: 'BRIVARACETAM (UCB34714)' NEUROTHERAPEUTICS V4 N1, 20061230, P84-87 * |
JPN6014020711; Epilepsia 44,Suppl.9, 2003, p.260-261,2.245 * |
JPN6014020712; Epilepsia 44,Suppl.9, 2003, p.261,2.246 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013537238A (ja) * | 2010-09-21 | 2013-09-30 | インテクリン・セラピユーテイクス・インコーポレイテツド | 抗糖尿病固体医薬組成物 |
JP2017039739A (ja) * | 2010-09-21 | 2017-02-23 | インテクリン・セラピユーテイクス・インコーポレイテツド | 抗糖尿病固体医薬組成物 |
JP2020532533A (ja) * | 2017-08-31 | 2020-11-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | 医薬剤形 |
JP7335870B2 (ja) | 2017-08-31 | 2023-08-30 | パーデュー、ファーマ、リミテッド、パートナーシップ | 医薬剤形 |
JP2022542533A (ja) * | 2020-07-09 | 2022-10-05 | 上海博志研新薬物技術有限公司 | ブリバラセタム医薬組成物、その製造方法及び応用 |
JP7423013B2 (ja) | 2020-07-09 | 2024-01-29 | 上海雲晟研新生物科技有限公司 | ブリバラセタム医薬組成物、その製造方法及び応用 |
Also Published As
Publication number | Publication date |
---|---|
HK1153141A1 (en) | 2012-03-23 |
US8435564B2 (en) | 2013-05-07 |
CN102046153A (zh) | 2011-05-04 |
ES2465478T3 (es) | 2014-06-05 |
CN102046153B (zh) | 2015-06-17 |
EP2285357B8 (en) | 2014-07-23 |
CA2722093C (en) | 2015-04-28 |
ES2465478T8 (es) | 2014-08-22 |
EP2285357B1 (en) | 2014-05-07 |
US20110091547A1 (en) | 2011-04-21 |
PL2285357T3 (pl) | 2014-08-29 |
DK2285357T3 (da) | 2014-06-02 |
BRPI0912161A2 (pt) | 2015-10-06 |
EP2285357A1 (en) | 2011-02-23 |
JP5553452B2 (ja) | 2014-07-16 |
CA2722093A1 (en) | 2009-12-03 |
WO2009144286A1 (en) | 2009-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5553452B2 (ja) | ブリバラセタムを含む医薬組成物 | |
EP3417861B1 (en) | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof | |
JP5183470B2 (ja) | レベチラセタムを含む薬剤組成物及びその調製方法 | |
JP5750847B2 (ja) | アトルバスタチン経口投与用粒子状医薬組成物 | |
EP2921170A1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
JP5576401B2 (ja) | 2−オキソ−1−ピロリジン誘導体を含む医薬組成物 | |
JP5534004B2 (ja) | 口腔内崩壊錠 | |
EP1507518B1 (en) | Combination immediate release controlled release levodopa/carbidopa dosage forms | |
TW201302198A (zh) | 含有納布啡(nalbuphine)之藥學組成物及其用途 | |
JP2015511635A (ja) | オルメサルタンメドキソミルとロスバスタチンまたはその塩とを含む医薬組成物 | |
EP2554159A1 (en) | Dosage forms comprising apixaban and content uniformity enhancer | |
EP3781135A2 (en) | Solid oral pharmaceutical compositions comprising sitagliptin | |
US20130344150A1 (en) | Direct compression tablets of otilonium | |
JP5415561B2 (ja) | Hcvポリメラーゼ阻害剤のプロドラッグを含む医薬組成物 | |
JP5614445B2 (ja) | 経口投与用粒子状医薬組成物 | |
EP3697392B1 (en) | Tablets comprising tamsulosin and solifenacin | |
JP4884772B2 (ja) | 経口徐放性錠剤 | |
KR20180088929A (ko) | 약학 조성물 | |
KR101506627B1 (ko) | 아세브로필린 및 친수성 서방기제를 포함하는 서방형 약학 조성물 | |
JP5525453B2 (ja) | 医薬組成物 | |
WO2005016315A1 (en) | Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler | |
JPH04305526A (ja) | 薬剤組成物 | |
KR20130076531A (ko) | 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130917 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140108 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140526 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5553452 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |